Finance

Lists
Why is EYPT up २.२७%?
Dive Deeper
EYPT:NASDAQ
EyePoint Inc
US$ ३.३८
+२.२७%
(+०.०७५) 1D
सेप्टेम्बर २९, १२:१७:५६ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EYPT...
Open
US$ ३.३१
High
US$ ३.४९
Low
US$ ३.३०
Mkt. cap
२९.१८ करोड
Avg. vol.
६२.३३ लाख
Volume
८.०३ लाख
52-wk high
US$ १९.०१
52-wk low
US$ ३.२६
EPS
-US$ ३.७४
Beta
१.६३
Shares outstanding
८.६२ करोड
No. of employees
२१४
Open
US$ ३.३१
High
US$ ३.४९
Low
US$ ३.३०
Mkt. cap
२९.१८ करोड
Avg. vol.
६२.३३ लाख
Volume
८.०३ लाख
52-wk high
US$ १९.०१
52-wk low
US$ ३.२६
EPS
-US$ ३.७४
Beta
१.६३
Shares outstanding
८.६२ करोड
No. of employees
२१४
Profile
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc. Wikipedia
About EyePoint Inc
CEO-
Employees२१४
Founded२०००
HeadquartersWatertown, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to EYPT in the past 3 months
Buy
Buy
6
Hold
6
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for EYPT in the last 3 months.
Highest
Current US$ ३.३८
US$ ४८.०० (+१,३१८.०२%)
Average
US$ २०.६७ (+५१०.६४%)
Lowest
US$ ४.०० (+१८.१७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Maintained
US$ २०.००
+४९०.८%
09/27/2026
Yigal Nochomovitz
Citi
Buy
Maintained
US$ १७.००
+४०२.२%
09/09/2026
Tara Bancroft
TD Cowen
Hold
Downgraded
US$ ४.००
+१८.२%
09/02/2026
Andreas Argyrides
Chardan Capital
Hold
Downgraded
US$ ५.००
+४७.७%
08/18/2026
Yi Chen
H.C. Wainwright
Hold
Downgraded
-
-
08/18/2026
Lisa Walter
RBC Capital
Hold
Downgraded
US$ ५.००
+४७.७%
08/17/2026
Yale Jen
Laidlaw
Buy
Maintained
US$ ४८.००
+१,३१८%
08/17/2026
Faisal Khurshid
Jefferies
Buy
Maintained
US$ ८.००
+१३६.३%
08/17/2026
Tessa Romero
J.P. Morgan
Hold
Downgraded
-
-
08/17/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Downgraded
-
-
08/17/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
US$ ३९.००
+१,०५२.१%
08/17/2026
Annabel Samimy
Stifel Nicolaus
Buy
Initiated
US$ ४०.००
+१,०८१.७%
07/16/2026
David Siffringer
Cantor Fitzgerald
Buy
Initiated
US$ ४७.००
+१,२८८.५%
07/08/2026
Daniil Gataulin
Chardan Capital
Buy
Maintained
US$ ६५.००
+१,८२०.२%
07/01/2026
Unknown Analyst
Jefferies
Buy
Maintained
US$ ३०.००
+७८६.३%
06/25/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
US$ ६८.००
+१,९०८.९%
06/24/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ ६८.००
+१,९०८.९%
06/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
९.६६ लाख
६.२० लाख
६.९६ लाख
५.०७ लाख
Cost of goods sold
४.७५ करोड
५.८६ करोड
७.१७ करोड
८.२६ करोड
Cost of revenue
४.७५ करोड
५.८६ करोड
७.१७ करोड
८.२६ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.५५ करोड
१.२४ करोड
१.६३ करोड
१.५३ करोड
Operating expense
१.५५ करोड
१.२४ करोड
१.६३ करोड
१.५३ करोड
Total operating expenses
६.३० करोड
७.१० करोड
८.७९ करोड
९.७९ करोड
Operating income
-६.२० करोड
-७.०३ करोड
-८.७२ करोड
-९.७४ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-५.९७ करोड
-६.७४ करोड
-८.४९ करोड
-९.४५ करोड
EBT excluding unusual items
-५.९७ करोड
-६.७४ करोड
-८.४९ करोड
-९.४५ करोड
Income tax expense
-
१.८६ लाख
-५०.०० हजार
-
Effective tax rate
-
-०.२८%
०.०६%
-
Other operating expenses
-
-
-
-
Net income
-५.९७ करोड
-६.७६ करोड
-८.४८ करोड
-९.४५ करोड
Net profit margin
-६,१८३.४४%
-१०,९०४.६८%
-१२,१८८.५१%
-१८,६३३.१४%
Earnings per share
-०.८५
-०.८१
-०.९९
-१.०९
Interest and investment income
२२.९३ लाख
२९.५५ लाख
२३.४४ लाख
२९.१० लाख
Interest expense
-
-३३.०० हजार
-
-
Net interest expenses
२२.९३ लाख
२९.२२ लाख
२३.४४ लाख
२९.१० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-६.१४ करोड
-६.९६ करोड
-८.६६ करोड
-९.६७ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू